Ridgeback Biotherapeutics in July will launch two phase 2 trials of its investigational antiviral EIDD-2801 as a potential COVID-19 treatment. Source: Devices & Diagnostics Letter
Faced with mounting evidence that hydroxychloroquine is ineffective in treating COVID-19, three trials of the drug have been terminated. Source: Devices & Diagnostics Letter
Gilead Sciences has gotten approval from the FDA to launch a phase 1 trial of an inhaled version of its antiviral remdesivir for the earlier treatment of COVID-19 patients. Source:…
Canadian sterile drug manufacturer Viatrexx was hit with an FDA warning letter for serious violations of aseptic practices observed during an agency inspection. Source: Devices & Diagnostics Letter
The system enables ear tube placements in five minutes. Source: Devices & Diagnostics Letter
The company plans to launch the product in the first half of 2021. Source: Devices & Diagnostics Letter
Glenmark is also conducting phase 3 trials of favipiravir as a COVID-19 monotherapy. Source: Devices & Diagnostics Letter
The FDA last week cleared EndeavorRx for marketing in the U.S. Source: Devices & Diagnostics Letter
Keytruda is now approved in China for three different types of cancer. Source: Devices & Diagnostics Letter
With just six months to go before the end of the transition period in the UK’s exit from the European Union, European drug industry groups said they are “extremely concerned”…